Filing Details

Accession Number:
0000925421-20-000254
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-17 17:47:16
Reporting Period:
2020-06-15
Accepted Time:
2020-06-17 17:47:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1563577 Galera Therapeutics Inc. GRTX Pharmaceutical Preparations (2834) V8
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1114448 Ag Novartis Lichtstrasse 35, Ch-4056
Basel V8 CH-4056
No No Yes No
1297709 Ltd Bioventures Novartis Forum 1 - 1.32, Lichtstrasse 35, Ch-4056
Basel V8 CH-4056
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-06-15 6,164 $9.05 3,483,395 No 4 S Direct
Common Stock Disposition 2020-06-16 8,600 $9.30 3,474,795 No 4 S Direct
Common Stock Disposition 2020-06-17 4,622 $9.27 3,470,173 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.00 to $9.10. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
  2. Novartis Bioventures Ltd is the record holder of the securities reported herein. As the indirect parent of Novartis Bioventures Ltd., Novartis AG may be deemed to share beneficial ownership of these securities.
  3. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.07 to $9.37. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
  4. Reflects sales of common stock executed in multiple transactions at prices ranging from $9.25 to $9.32. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.